Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort

Trottier, 2011, Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort, BJU Int, 108, E237, 10.1111/j.1464-410X.2011.10207.x Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 Gupta, 2010, A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands, Br J Cancer, 103, 708, 10.1038/sj.bjc.6605815 Steyerberg, 2009 Kranse, 2008, A graphical device to represent the outcomes of a logistic regression analysis, Prostate, 68, 1674, 10.1002/pros.20840 Kranse, 1999, Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region), Prostate, 39, 316, 10.1002/(SICI)1097-0045(19990601)39:4<316::AID-PROS14>3.0.CO;2-O Roobol, 2003, Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands), BJU Int, 92, 48, 10.1111/j.1464-410X.2003.04390.x DeLong, 1988, Comparing the areas under two of more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Heidenreich, 2011, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, 61, 10.1016/j.eururo.2010.10.039 Vickers, 2010, Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework, Semin Oncol, 37, 31, 10.1053/j.seminoncol.2009.12.004 Steyerberg, 2007, Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, J Urol, 177, 107, 10.1016/j.juro.2006.08.068 Schroder, 2003, Verification bias and the prostate-specific antigen test – is there a case for a lower threshold for biopsy?, N Engl J Med, 349, 393, 10.1056/NEJMe030073 Gosselaar, 2008, The interobserver variability of digital rectal examination in a large randomised trial for the screening of prostate cancer, Prostate, 68, 985, 10.1002/pros.20759 Boevee, 2010, Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer, Eur J Cancer, 46, 3082, 10.1016/j.ejca.2010.09.033 Gosselaar, 2008, The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer, BJU Int, 101, 685, 10.1111/j.1464-410X.2007.07309.x Cavadas, 2010, Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort, Eur Urol, 58, 551, 10.1016/j.eururo.2010.06.023 van den Bergh, 2008, The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison, BJU Int, 102, 1068, 10.1111/j.1464-410X.2008.07940.x Al-Azab, 2007, Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0ng/mL, Urology, 69, 103, 10.1016/j.urology.2006.09.041 Hammerer, 1995, Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate, J Urol, 153, 111, 10.1097/00005392-199501000-00038 Scattoni, 2006, Systematic prostate biopsies are more and more often becoming saturation biopsies, Eur Urol, 50, 202, 10.1016/j.eururo.2006.01.040 Karakiewicz, 1997, Outcome of sextant biopsy according to gland volume, Urology, 49, 55, 10.1016/S0090-4295(96)00360-3 Guichard, 2007, Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients, Eur Urol, 52, 430, 10.1016/j.eururo.2007.02.062 Liu, 2011, Small prostate size and high grade disease-biology or artifact?, J Urol, 185, 2108, 10.1016/j.juro.2011.02.053 Chen, 1999, Prostate cancer detection: relationship to prostate size, Urology, 53, 764, 10.1016/S0090-4295(98)00574-3 van Vugt, 2011, Prediction of prostate cancer in unscreened men: external validation of a risk calculator, Eur J Cancer, 47, 903, 10.1016/j.ejca.2010.11.012 Neill, 2008, Systematic lateral prostate biopsy – are the benefits worth the costs?, J Urol, 179, 1321, 10.1016/j.juro.2007.11.065 Gore, 2001, Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer, J Urol, 165, 1554, 10.1016/S0022-5347(05)66347-1 Durkan, 2002, Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol, BJU Int, 89, 33, 10.1046/j.1464-410X.2002.02555.x Kattan, 2006, Validating a prognostic model, Cancer, 107, 2523, 10.1002/cncr.22314 Eichler, 2006, Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review, J Urol, 175, 1605, 10.1016/S0022-5347(05)00957-2 Bul, 2011, Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3 ng/ml who are participating in the ERSPC Rotterdam, Eur Urol, 59, 498, 10.1016/j.eururo.2011.01.001 van Leeuwen, 2010, Balancing the harms and benefits of early detection of prostate cancer, Cancer, 116, 4857, 10.1002/cncr.25474